How come #COVID19 is mostly mild in children? And why do #MISC affect mostly young people?
An interesting hypothesis by @BrodinPetter considering the trade-off between growth and immunity, while most of the studies focus on resistance rather than tolerance 1/
Tolerance to the initial infection may allow virus to stay in gut longer, leak through gut wall, and trigger T cell activation. Could a milder systemic immune response lead to viral persistence in the gut of children? 2/
“Energy allocation for growth increases the threshold to mount expensive systemic inflammatory responses unless absolutely required” 3/
Indeed a thought provoking hypothesis of why kids can have mild COVID then develop severe MIS-C weeks to months later. Tolerance to the initial infection may allow virus to stay in gut longer, leak thru gut wall, & trigger T cell activation. 4/
There is an earlier review on, “Why is COVID-19 less severe in children?” The review also discusses the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections 5/
This study from #Singapore compares the immune characteristics of 55 patients with vaccine breakthrough #SARSCoV2 infection and 86 uninfected vaccinated close contacts. 1/
Antibody levels, including neutralizing antibodies, were similar in vaccine breakthrough patients and close contacts. 2/
Memory B cell levels, as assessed by B cell ELISpot, were lower in vaccine breakthrough patients than close contacts. 3/
A lot of people around the world are feeling elated & treating emergence of #Omicron as a signal of the end of the pandemic! Most believe it will bring “endemicity".
Does it make sense? 1/
How can anyone think we’ve got this under control when a new #variant suddenly pops up, nearly completely evades immunity & then sweeps the world in a few weeks?
Further, we must know “mutations have no schedule.” Could be 4-6 months, could be next week. 2/
“to what extent will #Omicron-like emergence events characterize "endemic" circulation of #SARS2? Given it occurred once, having it occur again would not be at all surprising,…whether to expect this every year or every ten.” 3/
What do we know about BA.2-sub-lineage of Omicron? Is BA.2 different?
BA.2 shares 32 mutations w/ BA.1, but it also has 28 unique mutations. Some diff in S1. E is the same, N & M are diff in 1 mutation between the two variants.
And...quite a difference when we go to ORF1ab. 1/
1-Transmissibility:
Consistent growth across multiple countries is evidence BA.2 may be some degree more transmissible than BA.1.
2-Virulence:
*Very* early observations from India and Denmark suggest there is no dramatic difference in severity compared to BA.1. 2/
3-Immune evasion:
Minimal differences in VE ag. BA.1 & BA.2 and, its also highly likely BA.1 infection will give decent cross-reactivity ag BA.2 infection.
4-Antigenicity:
The Spike RBD mutations are likely to have a fairly minimal impact on antigenicity compared to BA.1. 3/
1-The dysregulation of innate and adaptive immunity has been recognized to play a critical role in the clinical outcome of COVID-19 patients. 1/
2-Severe evolution of COVID is thought to be driven by hyperactivated innate immunity in addition to adaptive immune defects resulting in lymphopenia & neutrophils/lymphocytes imbalance
3-A deficient IFN response has also been shown to favor or result from SARS2 infection 2/
These immunological dysregulations are thus underlying hyper-immune reactions such as the “cytokine storm” syndrome, MIS-C, dysregulation of coagulation, as well as neurological & various other manifestations 3/
#COVID19 breakthrough infection after #CoronaVac inactivated vaccine induced robust antibody responses & cross-neutralization of #SARS2 variants, but less immunity against #Omicron
1/
Binding antibody levels in sera from patients with breakthrough infection (BI) were significantly higher than those in individuals who had received AstraZeneca Vaccine as a third vaccination. 2:
However, neutralizing activities against wild-type and variants including Alpha, Beta, & Delta were comparable in patients with BI & individuals who received a 3rd vaccination with AZ vax, which activities are exceeding 90%. 3/
A new modelling study on the value of vaccine boosters to mitigate the global impact of #Omicron
By fitting an immunological model to population-level vaccine effectiveness (VE) data, NAb titres for Omicron are reduced by 3.9 fold compared to the Delta variant 1/
Under this model, it is predicted that 90 days after boosting with the Pfizer-BioNTech vaccine, efficacy against severe disease (admission to hospital) declines to 95.9% against the Delta & 78.8% against the Omicron 2/
Integrating this immunological model within a model of SARS2 transmission, the size of the Omicron wave will depend on the degree of past exposure to infection across the population, w/ relatively small Omicron waves in countries that previously experienced a large Delta wave 3/